Here is why Pfizer's newfound momentum could set the stock up to soar in 2026. Pfizer's generous dividend has become a big ...

President Donald Trump has been threatening tariffs on pharmaceuticals for months. This week, he told CNBC that he’s planning ...

The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market ...

After beating AstraZeneca’s Calquence in quarterly revenue for the first time at the end of 2024, BeOne Medicines’ Brukinsa ...

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

The committee’s actions showed how even with lawmakers away from Washington on a monthlong break, interest in the Epstein ...

Pfizer CEO says drugmakers ‘are all ready to roll up their sleeves and execute’ as president demands more direct-to-consumer ...

Pfizer Q2 2025 earnings show 10% revenue growth, raised EPS guidance, strong R&D, and operational execution. Explore growth drivers and policy risks.

President Donald Trump said his administration is prepared to increase the tariffs it plans to impose on pharmaceuticals up ...

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% ...